DYN (Dyne Therapeutics) Long-Term Debt: $199.33 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DYN Dyne Therapeutics Inc DYN
34 GF Score
Price $26.49
! 2 Warning Signs
View Full Analysis

What is Dyne Therapeutics Long-Term Debt?

Dyne Therapeutics DYN +0.95% 34 Long-Term Debt is $199.33 Mil as of Jun. 2026. GuruFocus rates DYN with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Dyne Therapeutics's Long-Term Debt for the quarter that ended in Jun. 2026 was $199.33 Mil.

Dyne Therapeutics's quarterly Long-Term Debt increased from Dec. 2025 ($148.92 Mil) to Mar. 2026 ($149.38 Mil) and increased from Mar. 2026 ($149.38 Mil) to Jun. 2026 ($199.33 Mil).

Dyne Therapeutics's annual Long-Term Debt stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($148.92 Mil).

Dyne Therapeutics  (NAS:DYN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Dyne Therapeutics Long-Term Debt Related Terms

Dyne Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Dyne Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dyne Therapeutics Long-Term Debt Chart

Dyne Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 148.92

Dyne Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.81 99.15 148.92 149.38 199.33
DYN
34GF Score
Dyne Therapeutics Inc DYN
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $199.33 Mil mean?
Dyne Therapeutics (DYN) has a Long-Term Debt of $199.33 Mil as of Jun. 2026.
Is Dyne Therapeutics' Long-Term Debt too high?
Dyne Therapeutics' current Long-Term Debt is $199.33 Mil. Overall, Dyne Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Dyne Therapeutics' Long-Term Debt compare to VKTX and CELC?
Dyne Therapeutics' Long-Term Debt of $199.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Dyne Therapeutics's current Long-Term Debt is $199.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dyne Therapeutics stock overvalued right now?
Dyne Therapeutics (DYN) has a current Long-Term Debt of $199.33 Mil. The current Long-Term Debt is $199.33 Mil. Dyne Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Dyne Therapeutics (DYN), the current Long-Term Debt is $199.33 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dyne Therapeutics Business Description

Address 1560 Trapelo Road, Waltham, MA, USA, 02451
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
34GF Score

Get the complete analysis for DYN

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.49
Price